Women's Health & Gynecology Clinical Trials Update: Week 19, 2026

Published May 8, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Mobile Web App Intervention to Promote Cervical Cancer Screening

This study is testing a mobile web app designed to encourage cervical cancer screening among Indigenous women aged 25 to 65 on the Yankton Sioux Tribe Reservation in South Dakota. By using culturally tailored messages and support, the app aims to increase screening rates, which can lead to earlier detection of cervical cancer and better health outcomes. The study follows 120 women for up to six months after using the app to see if it makes a difference in screening behavior.

A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)

This international phase II trial is exploring new treatment options for women with recurrent clear cell carcinoma of the ovaries, uterus, cervix, vulva, or vagina. It compares the immune therapy drug dostarlimab alone or combined with bevacizumab against a standard chemotherapy regimen. If these treatments prove to be effective and better tolerated, they could provide new hope for patients facing this difficult-to-treat cancer. The study plans to enroll 198 participants worldwide.

Prevention and Early Detection of Cervical Cancer Through Self-Administered Screening

This study is evaluating a self-administered HPV test for women aged 25 to 49 in Uganda to detect cervical cancer early. Making screening easier and more accessible outside of clinics could help more women get tested and catch cancer sooner when it is most treatable. With over 2,500 participants, this study could influence how cervical cancer screening is offered in communities with limited healthcare access.

Rosie the Chatbot: Leveraging Automated and Personalized Health Information Communication

This study tested an educational chatbot called Rosie that provides personalized health information to pregnant and postpartum women in the United States. Available in English and Spanish, Rosie offers quick, confidential answers to support maternal mental health and infant care. The trial with 400 participants has been completed, and the chatbot could be a helpful tool for new mothers seeking reliable information anytime.

SmartMom: Teaching by Texting to Promote Health Behaviours in Pregnancy

SmartMom is a text messaging program designed to encourage healthy habits during pregnancy. This Canadian study is recruiting pregnant people to see if receiving tailored health messages by text can improve knowledge, mental health, and pregnancy outcomes. If successful, this easy-to-use program could reach many expecting families and support healthier pregnancies through mobile technology.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.